Lithium for Low-Grade Neuroendocrine Tumors

Phase 2 Completed 15 enrolled University of Wisconsin, Madison National Cancer Institute (NCI) · collab National Institutes of Health (NIH) · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to learn more about the effectiveness and side effects of lithium treatment for subjects with low-grade neuroendocrine tumors.

Timeline

Start: 2007-07
Primary completion: 2009-06
Completion: 2009-06

Publications

Results Lubner SJ, Kunnimalaiyaan M, Holen KD, Ning L, Ndiaye M, Loconte NK, Mulkerin DL, Schelman WR, Chen H. A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist. 2011;16(4):452-7. doi: 10.1634/theoncologist.2010-0323. Epub 2011 Mar 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lithium	Unknown	300 mg	Oral

Lithium for Low-Grade Neuroendocrine Tumors

Summary

Timeline

Publications

Drugs

Indications